Primary systemic therapy on local advance breast cancer, where are we going?

Annals of Oncology

Volumn 17, Issue SUPPL. 7, 2006, Pages

  Cinieri, Saverio ^a   Orlando, L ^a   Colleoni, M ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Bevacizumab; Breast cancer; Primary chemotherapy; rhuMAb

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CISPLATIN; FLUOROURACIL; GONADORELIN DERIVATIVE; LETROZOLE; NAVELBINE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; TRIPTORELIN; VASCULOTROPIN;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BLOOD VESSEL PERMEABILITY; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CELL GROWTH; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; ENDOTHELIUM CELL; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; HYPERTENSION; INHIBITION KINETICS; MONOTHERAPY; NAUSEA AND VOMITING; NEPHROTIC SYNDROME; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROTEINURIA; THROMBOEMBOLISM; THROMBOSIS;

EID: 33745616823     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl943     Document Type: Article

References (26)

1. Fisher B, Briant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
2. Bonadonna G. Evolving concepts in the systemic ajuvant treatment of breast cancer. Cancer Res 1992; 52: 2127-2137.
3. Hortobagyi GN, Ames FC, Buzdar AU et al. Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 1988; 62: 2507-2516.
4. Smith IE, Walsh G, Jones A et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995; 13: 424-429.
5. Powels TJ, Hickish TF, Makris A et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer J Clin Oncol 1995; 13: 547-552.
6. Ellis PA, Smith IE, Detre S et al. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 1998; 48: 107-116.
7. Chang J, Powles TJ, Allred DC et al. Predictive markers for clinical outcome following primary chemotherapy for operable breast cancer. Proc Am Soc Clin Oncol 1998; 17: 384.
8. Makris A, Powles TJ, Allred DC et al. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat 1998; 48: 11-20.
9. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-3816.
10. Dixon JM, Renshaw L, Bellamy C et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: A randomized, double-blind, single-center study. Clin Cancer Res 2000; 6: 2229-2235.
11. Smith IE, Walsh G, Jones A et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995; 13: 424-429.
12. Smith IC, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-1466.
13. Dvorak HF, Brown LF, Detmar M et al. Vascular permeability factor, vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039.
14. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850.
15. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850.
16. Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 2001; 19: 851-856.
17. Langmuir VK, Cobleigh MA, Herbst RS et al. Successful long-term therapy with bevacizumab (Avastin™) in solid tumors. Proc Am Soc Clin Oncol 2002; 21: 9a.
18. Sledge GW, Cobleigh MA, Langmuir VK et al. A phase II dose-escalation trial of bevacizumab (Avastin) in previously treated metastatic breast cancer. Semin Oncol 2003; 30 (5 Suppl 16): 117-124.
19. Burstein HJ, Parker LM, Savoie J et al. Phase II trial of the antiVEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat 2002; 76 (Suppl 1): S115.
20. Miller KD, Rugo HS, Cobleigh MA. Phase III trial of capecitabine (Xeloda®) plus bevacizumab (Avastin™) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 2002; 76 (Suppl 1): S37.
21. Miller KD et al. Advances in monoclonal antibody therapy for breast cancer. Oral presentation during symposium. ASCO 2005.
22. Overmoyer B, Silverman P, Leeming R et al. Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. Breast cancer Res Treat 2004; 88: S106.
23. Wedam S, Low J, YangX et al. A pilot study to evaluate response and angiogenesis after treatment with bevacizumab in patients with inflammatory breast cancer. Proc AM Soc Clin Oncol 2004; 23: 21.
24. Van der Hage JA, Van de Velde CJH, Julien JP et al. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001; 19: 4224-4237.
25. Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patients with breast cancer no expressing steroid hormone receptors: A study of preoperative treatment. Clin Cancer Res 2004;10: 6622-6628.
26. Sataloff DM, Mason BA, Prestipino AJ et al. Pathological response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg 1995; 180: 297-304.